ATE355102T1 - 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6- methoxypyrid-3-yl) pyrazolo- 1,5-aö-1,3,5-triazin,seine enantiomeren und pharmazeutisch annehmbare salze als corticotropin-releasing-factor-rezeptor-ligande - Google Patents
4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6- methoxypyrid-3-yl) pyrazolo- 1,5-aö-1,3,5-triazin,seine enantiomeren und pharmazeutisch annehmbare salze als corticotropin-releasing-factor-rezeptor-ligandeInfo
- Publication number
- ATE355102T1 ATE355102T1 AT02713776T AT02713776T ATE355102T1 AT E355102 T1 ATE355102 T1 AT E355102T1 AT 02713776 T AT02713776 T AT 02713776T AT 02713776 T AT02713776 T AT 02713776T AT E355102 T1 ATE355102 T1 AT E355102T1
- Authority
- AT
- Austria
- Prior art keywords
- methoxypyrid
- pyrazolo
- butylamino
- enantiomers
- triazine
- Prior art date
Links
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical compound C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title 1
- 108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 title 1
- 102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27540301P | 2001-03-13 | 2001-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE355102T1 true ATE355102T1 (de) | 2006-03-15 |
Family
ID=23052141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02713776T ATE355102T1 (de) | 2001-03-13 | 2002-03-06 | 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6- methoxypyrid-3-yl) pyrazolo- 1,5-aö-1,3,5-triazin,seine enantiomeren und pharmazeutisch annehmbare salze als corticotropin-releasing-factor-rezeptor-ligande |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US20030125330A1 (de) |
| EP (1) | EP1368094B1 (de) |
| JP (1) | JP4549630B2 (de) |
| KR (1) | KR100875595B1 (de) |
| CN (1) | CN100427093C (de) |
| AR (1) | AR032986A1 (de) |
| AT (1) | ATE355102T1 (de) |
| AU (1) | AU2002245605B2 (de) |
| BG (1) | BG66331B1 (de) |
| BR (1) | BR0208357A (de) |
| CA (1) | CA2440553C (de) |
| CY (1) | CY1106607T1 (de) |
| CZ (1) | CZ20032481A3 (de) |
| DE (1) | DE60218434T2 (de) |
| DK (1) | DK1368094T3 (de) |
| EE (1) | EE05433B1 (de) |
| ES (1) | ES2282401T3 (de) |
| GE (1) | GEP20053608B (de) |
| HR (1) | HRP20030822B1 (de) |
| HU (1) | HU229317B1 (de) |
| IL (2) | IL157615A0 (de) |
| IS (1) | IS2839B (de) |
| MX (1) | MXPA03008185A (de) |
| MY (1) | MY146935A (de) |
| NO (1) | NO328580B1 (de) |
| NZ (1) | NZ528207A (de) |
| PL (1) | PL208278B1 (de) |
| PT (1) | PT1368094E (de) |
| RS (1) | RS50863B (de) |
| RU (1) | RU2292347C2 (de) |
| SK (1) | SK287603B6 (de) |
| TW (1) | TWI257388B (de) |
| UA (1) | UA74634C2 (de) |
| WO (1) | WO2002072202A1 (de) |
| ZA (1) | ZA200306995B (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094782B1 (en) * | 1996-07-24 | 2006-08-22 | Bristol-Myers Squibb Company | Azolo triazines and pyrimidines |
| ES2282401T3 (es) * | 2001-03-13 | 2007-10-16 | Bristol-Myers Squibb Pharma Company | 4-(2-butilamino)-2,7-dimetil-8-(2-metil-6-metoxipirid-3-il) pirazolo - 1,5-a-1,3,5-triazina, sus enantiomeros y sales farmaceuticamente aceptables como ligandos del receptor del factor liberador de croticotropina. |
| FR2842809A1 (fr) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION |
| AR041470A1 (es) * | 2002-10-17 | 2005-05-18 | Upjohn Co | Compuestos de pirrolo (1,2 - b) piridazina y sus usos |
| US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7041671B2 (en) | 2003-04-02 | 2006-05-09 | Pfizer Inc | Pyrrolo[1,2-b]pyridazine compounds and their uses |
| US7034023B2 (en) * | 2003-04-04 | 2006-04-25 | Pfizer Inc | Pyrrolo[1,2-B]pyridazine compounds and their uses |
| US7056920B2 (en) | 2003-04-04 | 2006-06-06 | Pfizer Inc | Pyrrolo[1,2-B]pyridazine compounds and their uses |
| BRPI0409444A (pt) * | 2003-04-15 | 2006-04-18 | Pharmacia & Upjohn Co Llc | compostos de pirrolo[1,2-b]piridazina e suas utilizações |
| US7208596B2 (en) * | 2003-11-25 | 2007-04-24 | Bristol-Myers Squibb Pharma Company | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof |
| US7153961B2 (en) | 2003-11-25 | 2006-12-26 | Bristol-Myers Squibb Pharma Co. | Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist |
| KR101088239B1 (ko) | 2006-09-20 | 2011-11-30 | 일라이 릴리 앤드 캄파니 | Ｃｒｆ１ 수용체 길항제로서의 티아졸 피라졸로피리미딘 |
| JP2015516979A (ja) * | 2012-04-23 | 2015-06-18 | ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーＨｏｌｓｂｏｅｒｍａｓｃｈｍｅｙｅｒ Ｎｅｕｒｏｃｈｅｍｉｅ Ｇｍｂｈ | Ｃｒｈ過剰活性を有する患者の治療に用いるためのｃｒｈｒ１アンタゴニスト |
| GB201210686D0 (en) | 2012-06-15 | 2012-08-01 | Holsboermaschmeyer Neurochemie Gmbh | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| GB201310782D0 (en) | 2013-06-17 | 2013-07-31 | Max Planck Innovation Gmbh | Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms |
| KR102079844B1 (ko) | 2016-09-20 | 2020-02-20 | 가톨릭대학교 산학협력단 | 담석 용해제를 포함하는 담낭 질환 치료용 약학 조성물 |
| BR112020002967A2 (pt) | 2017-08-14 | 2020-08-11 | Spruce Biosciences, Inc. | antagonistas de receptor de fator de liberação de corticotropina |
| MX2020011344A (es) | 2018-04-27 | 2021-02-09 | Spruce Biosciences Inc | Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios. |
| JP2023537598A (ja) | 2020-08-12 | 2023-09-04 | スプルース バイオサイエンシーズ，インク． | 多嚢胞性卵巣症候群を処置するための方法および組成物 |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW370529B (en) | 1992-12-17 | 1999-09-21 | Pfizer | Pyrazolopyrimidines |
| JP3398152B2 (ja) | 1993-10-12 | 2003-04-21 | ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー | １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体 |
| TW574214B (en) | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| CA2249598A1 (en) | 1996-03-26 | 1997-10-02 | Paul Joseph Gilligan | Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives |
| US6107300A (en) | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
| WO1997044308A1 (en) | 1996-05-24 | 1997-11-27 | The Dow Chemical Company | Process for preparing aliphatic ester compounds and alkanols |
| AU747708B2 (en) | 1996-07-24 | 2002-05-23 | Du Pont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| US6191131B1 (en) | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| CZ299451B6 (cs) * | 1996-07-24 | 2008-07-30 | Bristol-Myers Squibb Pharma Company | [1,5-a]-Pyrazolo-1,3,5- triaziny jejich použití afarmaceutické kompozice na jejich bázi |
| PL332040A1 (en) * | 1996-08-28 | 1999-08-16 | Pfizer | Substitution 6,5-heterobicyclic derivatives |
| EP0994860A1 (de) | 1997-07-03 | 2000-04-26 | Du Pont Pharmaceuticals Company | Aryl- und arylamino-substituierte heteroringen als corticotropin freisetzende hormon antagonisten |
| UA62972C2 (en) | 1997-07-03 | 2004-01-15 | Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders | |
| JP2002507996A (ja) | 1997-07-03 | 2002-03-12 | デュポン ファーマシューティカルズ カンパニー | 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類 |
| WO1999011643A1 (en) | 1997-09-02 | 1999-03-11 | Du Pont Pharmaceuticals Company | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders |
| IL137019A0 (en) * | 1998-01-28 | 2001-06-14 | Du Pont Pharm Co | Azolo triazines and pyrimidines |
| US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| WO1999051608A1 (en) | 1998-04-03 | 1999-10-14 | Du Pont Pharmaceuticals Company | THIAZOLO[4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS |
| US6124463A (en) | 1998-07-02 | 2000-09-26 | Dupont Pharmaceuticals | Benzimidazoles as corticotropin release factor antagonists |
| IL144977A0 (en) * | 1999-05-21 | 2002-06-30 | Bristol Myers Squibb Co | Pyrrolotriazine derivatives and pharmaceutical compositions containing the same |
| ES2282401T3 (es) * | 2001-03-13 | 2007-10-16 | Bristol-Myers Squibb Pharma Company | 4-(2-butilamino)-2,7-dimetil-8-(2-metil-6-metoxipirid-3-il) pirazolo - 1,5-a-1,3,5-triazina, sus enantiomeros y sales farmaceuticamente aceptables como ligandos del receptor del factor liberador de croticotropina. |
-
2002
- 2002-03-06 ES ES02713776T patent/ES2282401T3/es not_active Expired - Lifetime
- 2002-03-06 CA CA2440553A patent/CA2440553C/en not_active Expired - Fee Related
- 2002-03-06 KR KR1020037011913A patent/KR100875595B1/ko not_active Expired - Fee Related
- 2002-03-06 IL IL15761502A patent/IL157615A0/xx unknown
- 2002-03-06 EP EP02713776A patent/EP1368094B1/de not_active Expired - Lifetime
- 2002-03-06 NZ NZ528207A patent/NZ528207A/en not_active IP Right Cessation
- 2002-03-06 HR HR20030822A patent/HRP20030822B1/xx not_active IP Right Cessation
- 2002-03-06 MX MXPA03008185A patent/MXPA03008185A/es active IP Right Grant
- 2002-03-06 CZ CZ20032481A patent/CZ20032481A3/cs unknown
- 2002-03-06 DK DK02713776T patent/DK1368094T3/da active
- 2002-03-06 BR BR0208357-4A patent/BR0208357A/pt active Search and Examination
- 2002-03-06 JP JP2002571157A patent/JP4549630B2/ja not_active Expired - Fee Related
- 2002-03-06 EE EEP200300435A patent/EE05433B1/xx not_active IP Right Cessation
- 2002-03-06 HU HU0303480A patent/HU229317B1/hu not_active IP Right Cessation
- 2002-03-06 CN CNB028064151A patent/CN100427093C/zh not_active Expired - Fee Related
- 2002-03-06 AU AU2002245605A patent/AU2002245605B2/en not_active Ceased
- 2002-03-06 US US10/092,312 patent/US20030125330A1/en not_active Abandoned
- 2002-03-06 RU RU2003130093/04A patent/RU2292347C2/ru not_active IP Right Cessation
- 2002-03-06 WO PCT/US2002/006837 patent/WO2002072202A1/en not_active Ceased
- 2002-03-06 GE GE5322A patent/GEP20053608B/en unknown
- 2002-03-06 RS YUP-715/03A patent/RS50863B/sr unknown
- 2002-03-06 SK SK1157-2003A patent/SK287603B6/sk not_active IP Right Cessation
- 2002-03-06 PT PT02713776T patent/PT1368094E/pt unknown
- 2002-03-06 DE DE60218434T patent/DE60218434T2/de not_active Expired - Lifetime
- 2002-03-06 AT AT02713776T patent/ATE355102T1/de active
- 2002-03-06 PL PL368644A patent/PL208278B1/pl unknown
- 2002-03-12 MY MYPI20020879A patent/MY146935A/en unknown
- 2002-03-13 AR ARP020100908A patent/AR032986A1/es not_active Application Discontinuation
- 2002-03-13 TW TW091104706A patent/TWI257388B/zh not_active IP Right Cessation
- 2002-06-03 UA UA2003109244A patent/UA74634C2/uk unknown
-
2003
- 2003-02-05 US US10/358,652 patent/US7157578B2/en not_active Expired - Lifetime
- 2003-08-27 IL IL157615A patent/IL157615A/en not_active IP Right Cessation
- 2003-09-08 ZA ZA200306995A patent/ZA200306995B/en unknown
- 2003-09-10 IS IS6947A patent/IS2839B/is unknown
- 2003-09-11 NO NO20034023A patent/NO328580B1/no not_active IP Right Cessation
- 2003-09-23 BG BG108189A patent/BG66331B1/bg unknown
-
2006
- 2006-11-07 US US11/593,715 patent/US7358252B2/en not_active Expired - Lifetime
-
2007
- 2007-05-18 CY CY20071100678T patent/CY1106607T1/el unknown
-
2008
- 2008-02-13 US US12/030,439 patent/US7662817B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS2839B (is) | 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-(1,5-A-)-1,3,5 triazine, handhverfur þess og lyfjafræðilega ásættanleg sölt sem tenglar við viðtaka fyrir "corticotropin releasing factor" | |
| DE50204394D1 (de) | Substituierte 2-oxo-3-phenyl-5-carbonylaminomethyl-1,3-oxazoline und ihre verwendung als antikoagulantien und antithrombotika | |
| NO20041176L (no) | Nye 4,5-dihydro- 1H-pyrazolderivater med CB1-antagonistisk aktivitet | |
| DE50213202D1 (de) | Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel | |
| DE50209483D1 (de) | Xanthinderivate, deren herstellung und deren verwendung als arzneimittel | |
| DE50015711D1 (de) | In 6-stellung substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel | |
| DE50311318D1 (de) | Neue substituierte imidazo-pyridinone und imidazo-pyridazinone, ihre herstellung und ihre verwendung als arzneimittel | |
| EE05223B1 (et) | Triasoloprimidiini hendid, meetod nende valmistamiseks ning nende kasutamine | |
| DE50312747D1 (de) | Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel | |
| ATE288898T1 (de) | Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten | |
| DE60203917D1 (de) | Phenylsulfonyl-1,3-dihydro-2h-indol-2-on derivate, deren herstellung und deren therapeutische verwendung | |
| DE50208895D1 (de) | Substituierte 2-thio-3, 5-dicyano-4-aryl-6-aminopyridine und ihre verwendung als adenosinrezeptor-selektive liganden | |
| ATE332294T1 (de) | Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung | |
| DE60204349D1 (de) | 4-(1,3,4-thiadiazolyl-2-yl)-1,4-diazabizyklo- 3.2.2 nonanderivate, ihre herstellung und ihre therapeutische verwendung | |
| DE50210986D1 (de) | Substituierte 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre verwendung als adenosinrezeptor-selektive liganden | |
| EE200300400A (et) | Pürimidiiniühendid, nende valmistamismeetod ning kasutamine | |
| DE60229673D1 (de) | Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden | |
| DE60025385D1 (de) | 2,4-diaminopyrimidinderivate als immunosuppressiva | |
| ATE267201T1 (de) | 4-(2-phenylthiazol-5-yl)1,4- diazabicyclo(3.2.2)nonanederivate, ihre herstellung und therapeutische verwendung | |
| DE60203197D1 (de) | 4-(oxadiazol-3-yl)-1,4-diazabizyklo[3.2.2]-nonanderivate, ihre herstellung und therapeutische verwendung | |
| DE60123458D1 (de) | Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden | |
| ATE312828T1 (de) | Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung | |
| DE60038911D1 (de) | 4-Phenylpiperazinyl, -piperidinyl und -tetrahydropyridyl-Derivate als Dopamin D4-Antagonisten | |
| ATE401333T1 (de) | 1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptors | |
| ATE329908T1 (de) | Arylethene-sulfonamid derivate, deren herstellung und deren verwendung als endothelin-antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1368094 Country of ref document: EP |